quarta-feira, 7 de outubro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· July 15, 2026

Sify reports Consolidated Financial Results for Q1 FY 2026-27

View original at globenewswire.com
Sify reports Consolidated Financial Results for Q1 FY 2026-27 Revenues of INR 12,352 Million. Adjusted EBITDA of INR 3,005 Million. Profit for the period INR 65 Million…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Adjusted EBITDA was INR 3,005 million, an increase of 42% over the same quarter last year.

    60% confidence

  • Revenue was INR 12,352 million, an increase of 15% over the same quarter last year.

    60% confidence

  • India's digital transformation is entering a phase of execution at scale, and Sify's integrated portfolio of Data Centers, Networks, and Digital Services positions it to support customers modernizing for an AI-enabled future.

    60% confidence

  • The cash balance at the end of the quarter was INR 4,597 million.

    60% confidence

  • During the quarter, Sify strengthened the operational foundations of its businesses through disciplined execution, improved resource utilization, and targeted investments, while continuing to invest in capacity expansion, network modernization, and technology platforms for AI, cloud, and data-intensive workloads.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
Sify reports Consolidated Financial Results for Q1 FY 2026-27 — Source | Via News | pt.VIA.NEWS